Table 1 Patient demographics and number of icatibant-treated attacks

Patients, n (%)

12 (3.5)

153 (44.7)

119 (34.8)

58 (17.0)

BMI (kg/m²)^a

 Mean ± SD

18.0 ± 0.5

22.2 ± 1.8

26.9 ± 1.3

34.5 ± 4.1

 Median (range)

18.1 (16.7–18.4)

22.4 (18.7–25.0)

26.6 (25.0–29.8)

33.3 (30.0–46.7)

Sex, n (%)

 Female

11 (91.7)

105 (68.6)

60 (50.4)

33 (56.9)

 Male

1 (8.3)

48 (31.4)

59 (49.6)

25 (43.1)

Age at enrollment (years), n (%)

 ≥ 12 to < 18

1 (8.3)

2 (1.3)

1 (0.8)

0

 ≥ 18 to < 30

8 (66.7)

53 (34.6)

24 (20.2)

10 (17.2)

 ≥ 30 to < 50

1 (8.3)

66 (43.1)

52 (43.7)

27 (46.6)

 ≥ 50 to < 65

1 (8.3)

27 (17.6)

30 (25.2)

16 (27.6)

 ≥ 65

1 (8.3)

5 (3.3)

12 (10.1)

5 (8.6)

Country, n (%)

 Austria

0

6 (3.9)

3 (2.5)

0

 Brazil

0

6 (3.9)

7 (5.9)

3 (5.2)

 Denmark

0

0

1 (0.8)

2 (3.4)

 France

2 (16.7)

45 (29.4)

21 (17.6)

8 (13.8)

 Germany

2 (16.7)

16 (10.5)

16 (13.4)

12 (20.7)

 Greece

0

3 (2.0)

3 (2.5)

1 (1.7)

 Israel

2 (16.7)

20 (13.1)

15 (12.6)

6 (10.3)

 Italy

1 (8.3)

18 (11.8)

14 (11.8)

4 (6.9)

 Spain

4 (33.3)

20 (13.1)

22 (18.5)

8 (13.8)

 Sweden

0

0

1 (0.8)

0

 United Kingdom

1 (8.3)

19 (12.4)

16 (13.4)

14 (24.1)

Ongoing long-term prophylaxis, n (%)

 n

3

75

58

33

 C1-INH^b

0

11 (14.7)

11 (19.0)

4 (12.1)

 Attenuated androgens^b

0

47 (62.7)

44 (75.9)

24 (72.7)

 Tranexamic acid^b

2 (66.7)

24 (32.0)

9 (15.5)

11 (33.3)

 Other^b

1 (33.3)

8 (10.7)

4 (6.9)

3 (9.1)

No. of icatibant-treated attacks during enrollment

104

1314

829

450

No. of icatibant-treated attacks per patient^c

 Mean ± SD

8.7 ± 13.5

8.6 ± 14.8

7.0 ± 11.3

7.8 ± 10.8

 Median (range)

4.0 (1–47)

4.0 (1–101)

3.0 (1–83)

3.5 (1–57)